Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin

<p>Abstract</p> <p>Background</p> <p>We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes.</p&g...

Full description

Bibliographic Details
Main Authors: Maeder Uwe, Morris David L, Doerfer Joerg, Stojadinovic Alexander, Esquivel Jesus, Chua Terence C, Pelz Joerg OW, Germer Christoph-Thomas, Kerscher Alexander G
Format: Article
Language:English
Published: BMC 2010-12-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/689
id doaj-f54934c866584d2aab50c34a88778906
record_format Article
spelling doaj-f54934c866584d2aab50c34a887789062020-11-25T00:05:19ZengBMCBMC Cancer1471-24072010-12-0110168910.1186/1471-2407-10-689Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal OriginMaeder UweMorris David LDoerfer JoergStojadinovic AlexanderEsquivel JesusChua Terence CPelz Joerg OWGermer Christoph-ThomasKerscher Alexander G<p>Abstract</p> <p>Background</p> <p>We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes.</p> <p>Methods</p> <p>One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test.</p> <p>Results</p> <p>Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001].</p> <p>Conclusion</p> <p>A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.</p> http://www.biomedcentral.com/1471-2407/10/689
collection DOAJ
language English
format Article
sources DOAJ
author Maeder Uwe
Morris David L
Doerfer Joerg
Stojadinovic Alexander
Esquivel Jesus
Chua Terence C
Pelz Joerg OW
Germer Christoph-Thomas
Kerscher Alexander G
spellingShingle Maeder Uwe
Morris David L
Doerfer Joerg
Stojadinovic Alexander
Esquivel Jesus
Chua Terence C
Pelz Joerg OW
Germer Christoph-Thomas
Kerscher Alexander G
Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
BMC Cancer
author_facet Maeder Uwe
Morris David L
Doerfer Joerg
Stojadinovic Alexander
Esquivel Jesus
Chua Terence C
Pelz Joerg OW
Germer Christoph-Thomas
Kerscher Alexander G
author_sort Maeder Uwe
title Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
title_short Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
title_full Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
title_fullStr Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
title_full_unstemmed Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin
title_sort evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (psdss) for peritoneal carcinomatosis of colorectal origin
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2010-12-01
description <p>Abstract</p> <p>Background</p> <p>We evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes.</p> <p>Methods</p> <p>One hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test.</p> <p>Results</p> <p>Median survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001].</p> <p>Conclusion</p> <p>A trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.</p>
url http://www.biomedcentral.com/1471-2407/10/689
work_keys_str_mv AT maederuwe evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT morrisdavidl evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT doerferjoerg evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT stojadinovicalexander evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT esquiveljesus evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT chuaterencec evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT pelzjoergow evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT germerchristophthomas evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
AT kerscheralexanderg evaluationofbestsupportivecareandsystemicchemotherapyastreatmentstratifiedaccordingtotheretrospectiveperitonealsurfacediseaseseverityscorepsdssforperitonealcarcinomatosisofcolorectalorigin
_version_ 1725425745832968192